Clinical Trial

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-10-23; most recent amendment 2025-10-10.
Status change: Recruiting → Active, Not Recruiting 2025-10-10
Status change: Not Yet Recruiting → Recruiting 2020-05-01
Trial Details
NCT Number NCT04139902
Lead Sponsor Diwakar Davar
Collaborators: Tesaro, Inc.
Conditions Melanoma Stage III, Melanoma Stage IV
Enrollment 48 participants
Start Date 2020-06-12
Primary Completion 2025-09-29 (estimated)
Study Completion 2029-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-15